10 news items
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
ALUR
AMD
APLD
20 Jun 24
. (NASDAQ:OCUL) gained 16% to $6.36 after TD Cowen upgraded the stock from Hold to Buy and raised its price target from $7 to $11
HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
TPST
20 Jun 24
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tempest Therapeutics (NASDAQ:TPST) with a Buy and maintains $47 price target.
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
ASLN
ASNS
BILI
20 Jun 24
. On Tuesday, JP Morgan analyst Daniel Chen upgraded Bilibili from Neutral to Overweight and announced a $21 price target
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
TPST
18 Jun 24
), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TPST
7 Jun 24
), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced
krzwy4arbls5f200j9ku0ezjvamb4a2vsyn3w1vs364b5
TPST
13 May 24
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tempest Therapeutics (NASDAQ:TPST) with a Buy and maintains $47 price target.
ka8u r6lsjjwzstwg83tftcpuvik4
TPST
10 May 24
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tempest Therapeutics (NASDAQ:TPST) with a Buy and maintains $47 price target.
qe0u7e6pvqrm1crjbp3pzsvm 6r09fyi
TPST
9 May 24
-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2024, and provided
77pyywa6yck dlxpfgjjqin909jt35gnhvw3xdckwf
ACB
AGS
AIH
5 Apr 24
coverage on Ardelyx with an Outperform rating and announced a price target of $14.
Yatsen Holding Limited
pxzm6 a7tn
TPST
4 Apr 24
. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics
- Prev
- 1
- Next